See more : M&A Capital Partners Co.,Ltd. (6080.T) Income Statement Analysis – Financial Results
Complete financial analysis of Progyny, Inc. (PGNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Progyny, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Guangdong Modern High-tech Fiber Co., Ltd (300876.SZ) Income Statement Analysis – Financial Results
- Entergy Corporation (ETY.DE) Income Statement Analysis – Financial Results
- Genimous Technology Co., Ltd. (000676.SZ) Income Statement Analysis – Financial Results
- PIX Transmissions Limited (PIXTRANS.BO) Income Statement Analysis – Financial Results
- Rocky Mountain High Brands, Inc. (RMHB) Income Statement Analysis – Financial Results
Progyny, Inc. (PGNY)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.progyny.com
About Progyny, Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.09B | 786.91M | 500.62M | 344.86M | 229.68M | 105.40M | 48.58M |
| Cost of Revenue | 849.80M | 619.59M | 388.49M | 274.80M | 184.18M | 85.97M | 41.18M |
| Gross Profit | 238.80M | 167.33M | 112.14M | 70.06M | 45.51M | 19.43M | 7.40M |
| Gross Profit Ratio | 21.94% | 21.26% | 22.40% | 20.32% | 19.81% | 18.44% | 15.23% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 117.13M | 98.33M | 59.62M | 46.71M | 23.93M | 15.60M | 14.15M |
| Selling & Marketing | 59.49M | 45.66M | 20.18M | 15.01M | 11.90M | 7.29M | 4.26M |
| SG&A | 176.62M | 143.98M | 79.80M | 61.71M | 35.83M | 22.89M | 18.41M |
| Other Expenses | 0.00 | 286.00K | -366.00K | 210.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 176.62M | 143.98M | 79.80M | 61.71M | 35.83M | 22.89M | 18.41M |
| Cost & Expenses | 1.03B | 763.57M | 468.28M | 336.51M | 220.01M | 108.85M | 59.59M |
| Interest Income | 0.00 | 814.00K | 461.00K | 121.00K | 58.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 814.00K | 461.00K | 121.00K | 58.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 2.28M | 1.60M | 1.30M | 1.91M | 2.13M | 1.88M | 1.56M |
| EBITDA | 64.47M | 24.94M | 33.64M | 10.25M | 11.81M | -1.57M | -9.45M |
| EBITDA Ratio | 5.92% | 3.17% | 6.72% | 2.97% | 13.06% | 1.30% | -17.97% |
| Operating Income | 62.18M | 23.34M | 32.34M | 8.35M | 27.85M | -3.45M | -11.01M |
| Operating Income Ratio | 5.71% | 2.97% | 6.46% | 2.42% | 12.13% | -3.28% | -22.65% |
| Total Other Income/Expenses | 8.51M | 1.10M | 95.00K | 331.00K | -18.23M | -3.44M | -1.45M |
| Income Before Tax | 70.69M | 24.44M | 32.44M | 8.68M | -8.56M | -6.89M | -12.46M |
| Income Before Tax Ratio | 6.49% | 3.11% | 6.48% | 2.52% | -3.73% | -6.54% | -25.64% |
| Income Tax Expense | 8.65M | -5.92M | -33.33M | -37.78M | 12.00K | -1.78M | -3.00K |
| Net Income | 62.04M | 30.36M | 65.77M | 46.46M | -8.57M | 661.00K | -12.45M |
| Net Income Ratio | 5.70% | 3.86% | 13.14% | 13.47% | -3.73% | 0.63% | -25.63% |
| EPS | 0.65 | 0.33 | 0.74 | 0.54 | -0.10 | 0.01 | -0.18 |
| EPS Diluted | 0.62 | 0.30 | 0.66 | 0.47 | -0.10 | 0.01 | -0.15 |
| Weighted Avg Shares Out | 95.02M | 92.20M | 89.11M | 85.72M | 83.57M | 81.56M | 70.59M |
| Weighted Avg Shares Out (Dil) | 100.67M | 99.96M | 100.36M | 99.06M | 83.57M | 81.56M | 81.56M |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progyny, Inc. - PGNY
NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Progyny, Inc. ("Progyny" or the "Company") (NASDAQ: PGNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progyny, Inc. - PGNY
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Progyny, Inc. ("Progyny" or the "Company") (NASDAQ:PGNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Progyny (PGNY) Crashes After Losing Significant Client - Hagens Berman
SAN FRANCISCO, Oct. 05, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Progyny, Inc. (NASDAQ: PGNY) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may assist the investigation to contact its...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progyny, Inc. - PGNY
NEW YORK, NY / ACCESSWIRE / October 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Progyny, Inc. ("Progyny" or the "Company") (NASDAQ:PGNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progyny, Inc. - PGNY
NEW YORK , Oct. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Progyny, Inc. ("Progyny" or the "Company") (NASDAQ: PGNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
PGNY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Progyny, Inc. and Encourages Investors to Contact the Firm!
NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. (“Progyny” or “the Company”) (NASDAQ: PGNY). Investors who purchased Progyny securities are encouraged to obtain...
Progyny, Inc. (PGNY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. ("Progyny" or "the Company") (NASDAQ:PGNY). Investors who purchased Progyny securities are encouraged to...
PGNY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Progyny, Inc. investment
NEW YORK, NY / ACCESSWIRE / October 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Progyny, Inc. ("Progyny, Inc.") (NASDAQ:PGNY) concerning possible violations of federal securities laws. Progyny disclosed in a filing with...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progyny, Inc. - PGNY
NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Progyny, Inc. ("Progyny" or the "Company") (NASDAQ:PGNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Bronstein, Gewirtz & Grossman, LLC Encourages Progyny, Inc. (PGNY) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. ("Progyny" or "the Company") (NASDAQ:PGNY). Investors who purchased Progyny securities are encouraged to...
Source: https://incomestatements.info
Category: Stock Reports